Related Experiment Video

Updated: Jan 2, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.0K

Targeting Mutant KRAS for Immunogenic Cell Death Induction

Lorenzo Galluzzi1

  • 1Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France.

Trends in Pharmacological Sciences
|December 11, 2019
PubMed

Insights

A new KRAS G12C inhibitor can trigger immunogenic cancer cell death. This discovery suggests it may be effective when combined with immune checkpoint blockers for cancer therapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Somatic KRAS mutations are prevalent in human cancers.
  • Targeted therapies for KRAS mutations have been limited until recently.
  • KRAS G12C is a specific mutation found in various tumor types.

Purpose of the Study:

  • To investigate the therapeutic potential of a KRAS G12C inhibitor.
  • To determine if the inhibitor can induce immunogenic cancer cell death.
  • To evaluate the inhibitor as a combination partner for immune checkpoint blockers.

Main Methods:

  • Utilized a clinically available KRAS G12C inhibitor.
  • Assessed the induction of immunogenic cancer cell death.
  • Evaluated the inhibitor's efficacy in combination with immune checkpoint blockers.

Main Results:

  • The KRAS G12C inhibitor demonstrated the ability to drive immunogenic cancer cell death.
  • This cell death mechanism has implications for immune system activation against tumors.
  • The findings support the potential of this inhibitor in combination therapies.

Conclusions:

  • Clinically available KRAS G12C inhibitors can induce immunogenic cancer cell death.
  • This property makes them promising candidates for combination therapy with immune checkpoint blockers.
  • Further research is warranted to explore the clinical utility of this combinatorial approach.
Keywords:
colorectal cancerlung adenocarcinomanivolumaboxaliplatinpembrolizumab

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
15.9K